Industry Focus
Here's why paying $2 million for Novartis' revolutionary gene therapy for SMA may not be as crazy as it sounds. 
Also, why shares slumped after BioMarin reported its gene therapy may virtually eliminate bleeding in hemophilia A patients.

Check out more of our content here:

Direct download: 20190529_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EST